JMP Securities Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock Price

Hookipa Pharma (NASDAQ:HOOK) had its price target trimmed by JMP Securities from $24.00 to $7.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a market outperform rating on the stock.

Separately, Royal Bank of Canada reduced their target price on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

Hookipa Pharma Trading Down 6.5 %

NASDAQ HOOK opened at $2.15 on Thursday. The business’s 50-day moving average price is $3.84 and its two-hundred day moving average price is $5.50. Hookipa Pharma has a 12 month low of $2.08 and a 12 month high of $11.30. The firm has a market capitalization of $25.93 million, a PE ratio of -0.58 and a beta of 0.84.

Institutional Investors Weigh In On Hookipa Pharma

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC raised its position in shares of Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the period. Renaissance Technologies LLC increased its position in shares of Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the last quarter. Ikarian Capital LLC purchased a new position in shares of Hookipa Pharma during the third quarter worth approximately $228,000. Finally, Virtu Financial LLC bought a new position in shares of Hookipa Pharma during the first quarter valued at about $31,000. 63.88% of the stock is owned by hedge funds and other institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.